Ensuring Impact of Long-acting HIV Therapeutics Through Multi-level Treatment Research: a View from NIH

Overview

Journal J Int AIDS Soc

Specialty Infectious Diseases

Date 2023 Jul 13

PMID 37439059

Authors

Peter S Kim

Michael J Stirratt

Tia M Morton

Dianne M Rausch

Affiliations

Soon will be listed here.

Citing Articles

Advancing use of long-acting and extended delivery HIV prevention and treatment regimens.

Delany-Moretlwe S, Flexner C, Bauermeister J J Int AIDS Soc. 2023; 26 Suppl 2:e26126.

PMID: 37439079 PMC: 10338994. DOI: 10.1002/jia2.26126.

References

Kalichman S, Katner H, Banas E, Hill M, Kalichman M . Cumulative Effects of Stigma Experiences on Retention in HIV Care Among Men and Women in the Rural Southeastern United States. AIDS Patient Care STDS. 2020; 34(11):484-490. PMC: 7698850. DOI: 10.1089/apc.2020.0144. View

Shubber Z, Mills E, Nachega J, Vreeman R, Freitas M, Bock P . Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016; 13(11):e1002183. PMC: 5127502. DOI: 10.1371/journal.pmed.1002183. View

Gaebler C, Nogueira L, Stoffel E, Oliveira T, Breton G, Millard K . Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022; 606(7913):368-374. PMC: 9177424. DOI: 10.1038/s41586-022-04597-1. View

Norcini Pala A, Kempf M, Konkle-Parker D, Wilson T, Tien P, Wingood G . Intersectional stigmas are associated with lower viral suppression rates and antiretroviral therapy adherence among women living with HIV. AIDS. 2022; 36(13):1769-1776. PMC: 9529955. DOI: 10.1097/QAD.0000000000003342. View

Garris C, Czarnogorski M, Dalessandro M, DAmico R, Nwafor T, Williams W . Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study. J Int AIDS Soc. 2022; 25(9):e26006. PMC: 9468562. DOI: 10.1002/jia2.26006. View

Chandiwana N, Serenata C, Owen A, Rannard S, Perez Casas C, Scott C . Impact of long-acting therapies on the global HIV epidemic. AIDS. 2021; 35(Suppl 2):S137-S143. DOI: 10.1097/QAD.0000000000003102. View

Bogart L, Barreras J, Gonzalez A, Klein D, Marsh T, Agniel D . Pilot Randomized Controlled Trial of an Intervention to Improve Coping with Intersectional Stigma and Medication Adherence Among HIV-Positive Latinx Sexual Minority Men. AIDS Behav. 2020; 25(6):1647-1660. PMC: 8084890. DOI: 10.1007/s10461-020-03081-z. View

Dillingham R, Ingersoll K, Flickinger T, Waldman A, Grabowski M, Laurence C . PositiveLinks: A Mobile Health Intervention for Retention in HIV Care and Clinical Outcomes with 12-Month Follow-Up. AIDS Patient Care STDS. 2018; 32(6):241-250. PMC: 5982157. DOI: 10.1089/apc.2017.0303. View

Benbow N, Mokotoff E, Dombrowski J, Wohl A, Scheer S . The HIV Treat Pillar: An Update and Summary of Promising Approaches. Am J Prev Med. 2021; 61(5 Suppl 1):S39-S46. PMC: 11107265. DOI: 10.1016/j.amepre.2021.05.028. View

10.

Dombrowski J, Galagan S, Ramchandani M, Dhanireddy S, Harrington R, Moore A . HIV Care for Patients With Complex Needs: A Controlled Evaluation of a Walk-In, Incentivized Care Model. Open Forum Infect Dis. 2019; 6(7):ofz294. PMC: 6641789. DOI: 10.1093/ofid/ofz294. View

11.

Hodge D, Back D, Gibbons S, Khoo S, Marzolini C . Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clin Pharmacokinet. 2021; 60(7):835-853. PMC: 8249281. DOI: 10.1007/s40262-021-01005-1. View

12.

Chounta V, Overton E, Mills A, Swindells S, Benn P, Vanveggel S . Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). Patient. 2021; 14(6):849-862. PMC: 8563641. DOI: 10.1007/s40271-021-00524-0. View

13.

Caskey M . Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr Opin HIV AIDS. 2019; 15(1):49-55. PMC: 7340121. DOI: 10.1097/COH.0000000000000600. View

14.

Christopoulos K, Grochowski J, Mayorga-Munoz F, Hickey M, Imbert E, Szumowski J . First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clin Infect Dis. 2022; 76(3):e645-e651. PMC: 9907477. DOI: 10.1093/cid/ciac631. View